The Company is a pharmaceutical company focused on bringing transformative medicine with known safety profiles to diseases with no effective first-line treatments. The Company intends to do this through the development of compounds with known activity and/or safety profiles. The Company’s lead program is designed to address neurological disorders through the therapeutic dosing of synthetic psilocybin. The Company is currently evaluating potential lead indications for its psilocybin-for-neurology program, which it refers to as its PFN™ program, including fibromyalgia and Prader-Willi Syndrome. In addition to its PFN™ program, the Company is developing razoxane for the treatment of soft-tissue sarcomas. The Company continues to evaluate potential additional indications for its existing programs, as well as other drug candidates with known activity and/or safety profiles that may have utility in the treatment of rare diseases or other diseases with high unmet medical needs.